Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Liraglutide recommended for weight loss
Although it has been unable to win a PBS listing for its initial indication in type 2 diabetes, Novo Nordisk's liraglutide has won a recommendation from the EU's CHMP for a new indication in weight loss.
Approvals Action
Lilly joins GLP-1 crew
Eli Lilly has won approval for once-weekly diabetes treatment Trulicity, joining Novo Nordisk and AstraZeneca in having GLP-1 drugs on the Australian register.
Open Forum
Sovereign question at heart of red tape review
The question of how much the government should give up of its sovereign right to decide which medicines come to Australia and how they come is emerging as central to the medicines regulation review.
Special Report
Cancer drugs at a crossroads
This year will be an important one for the future of cancer drug reimbursement in Australia with a Senate inquiry into the availability of new therapies due to report in March while the PBAC continues to see more and more cancer options submitted for public funding.
Special Report
International pharma on a roll for 2015
After being the gloomiest of all international industry sectors last year, pharma and healthcare executives' business expectations for 2015 have bounced back to earn them the 'most positive' award for 2015.